|1.||Kastner, Christof: 2 articles (12/2004 - 06/2003)|
|2.||Shore, Neal D: 1 article (09/2010)|
|3.||Sethi, Parminder S: 1 article (09/2010)|
|4.||Cabezas, Juan: 1 article (12/2004)|
|5.||Huidobro, Christian: 1 article (12/2004)|
|6.||Hochreiter, Werner: 1 article (12/2004)|
|7.||Miller, Paul: 1 article (12/2004)|
|8.||Parsons, Keith: 1 article (06/2003)|
|9.||Wiskott, Anselm H W: 1 article (06/2003)|
|10.||Coto-Hunziker, Viviana: 1 article (06/2003)|
|1.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
09/01/2010 - "Thirty-four men with symptomatic benign prostatic hyperplasia (BPH) were randomized to a single treatment with either the Prolieve or Targis system; 30 were treated and then followed for 6 months. "
09/01/2010 - "A controlled, randomized, head-to-head comparison of the Prolieve thermodilatation System versus the Targis System for benign prostatic hyperplasia: safety, procedural tolerability, and clinical results."
12/01/2004 - "Cooled TUMT, using the Targis system from Urologix, is an established treatment option for benign prostatic hyperplasia (BPH) with minimal side effects. "
06/01/1998 - "Contrasting heating patterns and efficiency of the Prostatron and Targis microwave antennae for thermal treatment of benign prostatic hyperplasia."
06/01/2002 - "We investigated the long-term efficacy of the second generation Targis thermotherapy device (Urologix, Inc., Minneapolis, Minnesota) for decreasing outflow obstruction caused by benign prostatic hyperplasia. "
02/01/2003 - "Between August 1997 and March 2001, a total of 78 patients in poor general health status presenting with large prostate glands and acute urinary retention secondary to BPH were treated with the Targis TUMT device. "
02/01/2003 - "To evaluate the Targis System in men presenting with acute urinary retention, high prostate volume and high operative risk. "
02/01/2003 - "Transurethral microwave thermotherapy (TUMT) with the Targis System: a single-centre study on 78 patients with acute urinary retention and poor general health."
02/01/2003 - "Following treatment, the mean peak flow rate in the 68 successfully treated patients was 11.1 ml/s, while the mean postvoid residual volume was 46 ml. Based on these data we recommend transurethral thermotherapy using the Targis System for patients in poor general health presenting with urinary retention and prostate volumes of more than 35 cc in whom TURP is not possible."
09/01/2010 - "Overall, the incidence of device-related adverse events was 31% (Prolieve) compared with 64% (Targis) (P > 0.05)-most prevalently, urinary retention, dysuria, and hematuria. "
|4.||Prostatic Neoplasms (Prostate Cancer)
|1.||Induced Hyperthermia (Thermotherapy)
|2.||Transurethral Resection of Prostate (TURP)
|3.||Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
|4.||Prostatectomy (Retropubic Prostatectomy)